- CFO Spotlights
- Profiles
- Faraz Ali, M.B.A.
Profile
Faraz Ali, M.B.A.
Chief Executive Officer and Director (Principal Executive Officer and Interim Principal Financial Officer), Tenaya Therapeutics, Inc.
Former. First published here October 28, 2026; built from records as of October 28, 2026.
Tenaya Therapeutics, Inc. named Eric Hyllengren, M.B.A. to succeed Faraz Ali, M.B.A., effective July 13, 2026.2
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| Tenaya Therapeutics, Inc. (TNYA) Biological Products, (No Diagnostic Substances) | Chief Executive Officer and Director (Principal Executive Officer and Interim Principal Financial Officer) | Former |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- July 13, 2026effective
Tenaya Therapeutics, Inc. named Eric Hyllengren, M.B.A. to succeed Faraz Ali, M.B.A., effective July 13, 2026. Profile of Eric Hyllengren, M.B.A..
On June 29, 2026, Tenaya Therapeutics, Inc. (the “Company”) announced that Eric Hyllengren, M.B.A., will join the Company as Chief Financial Officer on July 13, 2026 (the “Commencement Date”), and in such capacity, will serve as the Company’s […]
[2] Filing by Tenaya Therapeutics, Inc., filed with the SEC on June 29, 2026. Read the filing. The record at CFO Tribune.
- March 11, 202610-K filed
Faraz Ali, M.B.A. signed the annual report of Tenaya Therapeutics, Inc. on Form 10-K as Chief Executive Officer and Director (Principal Executive Officer and Interim Principal Financial Officer), filed March 11, 2026.
/s/ Faraz Ali, M.B.A. Chief Executive Officer and Director (Principal Executive Officer and Interim Principal Financial Officer)
[1] Annual report on Form 10-K by Tenaya Therapeutics, Inc., filed with the SEC on March 11, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Annual report on Form 10-K, Tenaya Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 11, 2026. sec.gov; record.
- Current report filed with the SEC, Tenaya Therapeutics, Inc.. U.S. Securities and Exchange Commission, EDGAR, filed June 29, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or Faraz Ali, M.B.A. wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.